Donated Blood Screening for HIV, HCV and HBV by ID-NAT and the Residual Risk of Iatrogenic Transmission in a Tertiary Care Hospital Blood Bank in Puebla, Mexico

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2023 Jun 28

PMID 37376630

Authors

Francisca Sosa-Jurado

Roxana Palencia-Lara

Cinthia Xicotencatl-Grijalva

Maribel Bernal-Soto

Alvaro Montiel-Jarquin

Yolanda Ibarra-Pichardo

Nora Hilda Rosas-Murrieta

Rosalia Lira

Paulina Cortes-Hernandez

Gerardo Santos-Lopez

Affiliations

Soon will be listed here.

Abstract

Hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV) can be transmitted by blood transfusion. Most transmission occurs during the acute viremic phase (AVP), before antibody development. To reduce transmission risk, individual donor nucleic acid testing (ID-NAT) is used. In Puebla, Mexico, serological tests and ID-NAT have been applied to screen blood donors and detect individuals in AVP. In the present study, 106,125 blood donors' data in two periods (2012-2015 and 2017-2019) were analyzed. The residual risk (RR) values were calculated considering ID-NAT results. The RR for HIV was 14 in 1 million donations or 1 in 71,428, the RR for HVC was 6.8 in 1 million donations or 1 in 147,058 and, for HBV, it was 156 in 1 million donations, or 1 in 6410. Previously, it was predicted that the transmission RR of these viruses would be reduced in Mexico through better screening with NAT. The use of ID-NAT has, indeed, increased the safety of blood reserves for HIV and HCV. However, more research is needed to determine why the residual risk of HBV did not decrease as much over the study period. ID-NAT is an important complementary tool for blood donor screening that should be implemented.

Citing Articles

Risk Factors Associated with Hepatitis C Subtypes and the Evolutionary History of Subtype 1a in Mexico.

Laguna-Meraz S, Jose-Abrego A, Roman S, Leal-Mercado L, Panduro A Viruses. 2024; 16(8).

PMID: 39205233 PMC: 11359553. DOI: 10.3390/v16081259.

An Update on Viral Hepatitis B and C in Mexico: Advances and Pitfalls in Eradication Strategies.

Campos-Valdez M, Castro-Garcia M, Ramos-Marquez M, Gurrola-Diaz C, Salazar-Montes A, Sanchez-Orozco L Microorganisms. 2024; 12(7).

PMID: 39065136 PMC: 11279215. DOI: 10.3390/microorganisms12071368.

Plasma Photoinactivation of Bacterial Isolated from Blood Donors Skin: Potential of Security Barrier in Transfusional Therapy.

Ventura-Enriquez Y, Casas-Guerrero A, Sanchez-Guzman M, Loyola-Cruz M, Cruz-Cruz C, Nolasco-Rojas A Pathogens. 2024; 13(7).

PMID: 39057804 PMC: 11280016. DOI: 10.3390/pathogens13070577.

Hepatitis B Virus Genotype H: Epidemiological, Molecular, and Clinical Characteristics in Mexico.

Panduro A, Roman S, Laguna-Meraz S, Jose-Abrego A Viruses. 2023; 15(11).

PMID: 38005864 PMC: 10675821. DOI: 10.3390/v15112186.

References

Cappy P, Boizeau L, Candotti D, Caparros R, Lucas Q, Garrabe E . Effectiveness of the HCV blood screening strategy through eighteen years of surveillance of HCV infection in blood donors in France. Blood Transfus. 2021; 20(1):1-7. PMC: 8796843. DOI: 10.2450/2021.0032-21. View

Grubyte S, Urboniene J, Nedzinskiene L, Jelinskaite A, Zagminas K, Ambrozaitis A . Prevalence, incidence and residual risk of transfusion transmitted viruses (HBV, HCV and HIV infections) in Lithuanian blood donors from 2004 to 2018: The incidence/window-period model study. PLoS One. 2021; 16(2):e0246704. PMC: 7894937. DOI: 10.1371/journal.pone.0246704. View

Laguna-Meraz S, Roman S, Jose-Abrego A, Sigala-Arellano R, Panduro A . A hospital-based study of the prevalence of HBV, HCV, HIV, and liver disease among a low-income population in West Mexico. Ann Hepatol. 2021; 27 Suppl 1:100579. DOI: 10.1016/j.aohep.2021.100579. View

Kershenobich D, Higuera-de-la Tijera F, Flores N, Cerda-Reyes E, Castro-Narro G, Aceves G . Hepatitis C screening and detection program in a large population: Epidemiological transition and characterization of the disease. Liver Int. 2023; 43(6):1225-1233. DOI: 10.1111/liv.15570. View

Dodd R, Crowder L, Haynes J, Notari E, Stramer S, Steele W . Screening Blood Donors for HIV, HCV, and HBV at the American Red Cross: 10-Year Trends in Prevalence, Incidence, and Residual Risk, 2007 to 2016. Transfus Med Rev. 2020; 34(2):81-93. DOI: 10.1016/j.tmrv.2020.02.001. View

Contreras A, Reta C, Torres O, Celis A, Dominguez J . [Safe blood in the absence of viral infections due to HBV, HCV and HIV in serological window period in donors]. Salud Publica Mex. 2011; 53 Suppl 1:S13-8. View

Parekh B, Ou C, Fonjungo P, Kalou M, Rottinghaus E, Puren A . Diagnosis of Human Immunodeficiency Virus Infection. Clin Microbiol Rev. 2018; 32(1). PMC: 6302353. DOI: 10.1128/CMR.00064-18. View

Jose-Abrego A, Panduro A, Fierro N, Roman S . High prevalence of HBV infection, detection of subgenotypes F1b, A2, and D4, and differential risk factors among Mexican risk populations with low socioeconomic status. J Med Virol. 2017; 89(12):2149-2157. DOI: 10.1002/jmv.24913. View

Dantes H, Farfan-Ale J, Sarti E . Epidemiological trends of dengue disease in Mexico (2000-2011): a systematic literature search and analysis. PLoS Negl Trop Dis. 2014; 8(11):e3158. PMC: 4222737. DOI: 10.1371/journal.pntd.0003158. View

10.

Garcia-Sepulveda C, Laguna-Meraz S, Panduro A . How far is Mexico from Viral Hepatitis Global Health Sector Strategy 2030 targets. Ann Hepatol. 2020; 19(2):123-125. DOI: 10.1016/j.aohep.2020.02.003. View

11.

Contreras A, Tornero-Romo C, Toribio J, Celis A, Orozco-Hernandez A, Rivera P . Very low hepatitis C antibody levels predict false-positive results and avoid supplemental testing. Transfusion. 2008; 48(12):2540-8. DOI: 10.1111/j.1537-2995.2008.01886.x. View

12.

Hourfar M, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch M . Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion. 2008; 48(8):1558-66. DOI: 10.1111/j.1537-2995.2008.01718.x. View

13.

Sosa-Jurado F, Santos-Lopez G, Guzman-Flores B, Ruiz-Conde J, Melendez-Mena D, Vargas-Maldonado M . Hepatitis C virus infection in blood donors from the state of Puebla, Mexico. Virol J. 2010; 7:18. PMC: 2829021. DOI: 10.1186/1743-422X-7-18. View

14.

Nishiya A, Levi J, de Almeida-Neto C, Witkin S, Ferreira S, Bassit L . Occult and active hepatitis B virus detection in donated blood in São Paulo, Brazil. Transfusion. 2021; 61(5):1495-1504. DOI: 10.1111/trf.16344. View

15.

Trevino-Perez S, Vega-Yanez A, Martinez-Abarca C, Estrada-Zarazua G, Perez-Camargo L, Borrayo-Sanchez G . [Medical Care of people living with HIV in the Instituto Mexicano del Seguro Social]. Rev Med Inst Mex Seguro Soc. 2023; 60(Suppl 2):96-102. PMC: 10651307. View

16.

Roth W . History and Future of Nucleic Acid Amplification Technology Blood Donor Testing. Transfus Med Hemother. 2019; 46(2):67-75. PMC: 6514489. DOI: 10.1159/000496749. View

17.

Liang P, Chen K, Huang C, Chang K, Lu P, Yeh M . Viral Interference Between Dengue Virus and Hepatitis C Virus Infections. Open Forum Infect Dis. 2020; 7(8):ofaa272. PMC: 7452371. DOI: 10.1093/ofid/ofaa272. View

18.

Hernandez-Avila M, Palacio-Mejia L, Hernandez-Avila J, Charvel S . [Vaccination in Mexico: imprecise coverages and deficiency in the follow-up of children with incomplete immunization]. Salud Publica Mex. 2020; 62(2):215-224. DOI: 10.21149/10682. View

19.

Higuera-de-la-Tijera F, Castro-Narro G, Velarde-Ruiz Velasco J, Cerda-Reyes E, Moreno-Alcantar R, Aiza-Haddad I . Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex (Engl Ed). 2021; 86(4):403-432. DOI: 10.1016/j.rgmxen.2021.04.002. View

20.

Cardenas-Perea M, Gomez-Conde E, Santos-Lopez G, Perez-Contreras I, Diaz-Orea M, Gandara-Ramirez J . Hepatitis B surface antibodies in medical students from a public university in Puebla, Mexico. Hum Vaccin Immunother. 2016; 12(7):1857-62. PMC: 4964820. DOI: 10.1080/21645515.2016.1151587. View